Scientists establish a foot in the door in precision medicine for oesophageal cancer

June 15, 2017 by Wendy Davidson
Scientists establish a foot in the door in precision medicine for oesophageal cancer
Credit: University of Aberdeen

Scientists at the Universities of Aberdeen and Dundee have established a foot in the door in finding new, precision treatments for patients with oesophageal cancer, one of the hardest forms of the disease to treat.

Professor Russell Petty, Chair of Medical Oncology in the University of Dundee School of Medicine led the decade long study into while at the University of Aberdeen. This research has culminated in a diagnostic test to establish which patients might benefit from a specific treatment. This can help predict which class of drugs may act to extend and improve quality of life for some patients.

By identifying which patients will benefit from being treated with the drug – and just as importantly identifying those who get no benefit from it – clinicians can focus on the best treatment plans in each case.

A clinical trial initiated by Professor Petty and colleagues in 2007 involving 450 patients in 50 hospitals across the United Kingdom looked at their responses to gefitinib. The researchers saw dramatic improvements in some patients who lived well beyond their initial prognosis of only weeks or months to live, in some cases by around 18 months to two years, and had improved quality of life.

Professor Petty explained: "After starting the trial we quickly observed very dramatic responses in some patients with improvement of their symptoms, and while not curative the responses were durable, lasting many months, for example up to two years in some cases.

"These responses to gefitinib were transformative to patients in this situation, moving them from being severely ill, with rapidly deteriorating health and within a few months of the end of their life, to a much improved condition where we had control of their 's growth and symptoms and they could return to 'normal life' with their families."

However, these responses occurred only in a minority, and the overwhelming majority of patients gained no benefit from gefitinib.

The research team carried out a detailed genetic analysis of biopsies of the patients' tumours to establish why some patients responded so well. As a result they have now developed a - the EGFR FISH test - that identifies those patients who will benefit from taking the drug.

Professor Zofia Miedzybrodzka, Chair in Applied Medicine at the University of Aberdeen who led the genetic testing part of the study explained: "By examining why some patients responded very well to gefitinib while others didn't, we have also learned more about how oesophageal cancer develops and what makes it so difficult to treat successfully,"

An estimated 455,000 individuals worldwide are diagnosed annually with oesophageal (or esophageal in American English) cancer and the rate has risen over the last four decades.

The disease has been notably resistant to treatment. While significant advances in treatment for other cancers have led to improved – around 50 per cent of patients with breast cancer, and 60 per cent of those with colon cancer, now recover – the rate for oesophageal cancer is only around 15 per cent.

Professor Petty clarified: "This research is extremely important because oesophageal cancer can be very aggressive and, without treatment or with ineffective treatment, many patients will unfortunately only have a short time to live.

"It is important to treat people with the medicine most likely to control the cancer first time around, as we may not get a second chance. Gefitinib, for example, only benefits around 1 in 10 patients, so it was vital we developed the test to identify which patients would and would not benefit.

"In those patients where we know gefitinib will not work, we can avoid proceeding with an ineffective treatment and give them the opportunity to try alternatives.

"This really is a foot in the door which will help us get better and more effective treatments for oesophageal cancer, using the same kind of precision treatment approaches which are already being applied in some other cancers.

"My hope is that our work is the end of the beginning in finding a range of precision treatments for patients with oesophageal cancer, which will lead to much better survival rates or extension of life."

Professor Petty added, "Gefitinib was the best of this class of medicine at the time we started our trial. Better drugs have since emerged in the same class, known as EGFR inhibitors, and our hope is that the same test we have developed to identify the patients that benefit from gefitinib will also work with these newer drugs."

The results of the research are reported in the Journal of Clinical Oncology, the leading journal in the field.

Explore further: Drug trial provides hope of new treatment for some oesophageal cancer patients

Related Stories

Drug trial provides hope of new treatment for some oesophageal cancer patients

August 22, 2014
Findings of a trial of a drug aimed at treating advanced oesophageal - or gullet - cancer could lead to a new treatment approach for a sub-group of patients with this kind of cancer.

Trial results reveal first targeted treatment to boost survival for oesophageal cancer

November 4, 2014
Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference ...

targeted therapy can delay recurrence of intermediate-stage lung cancer

May 18, 2017
The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor ...

Research suggests possible new treatment for EGFR-positive lung cancer

June 5, 2017
Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Compared to the ...

Study opens door to targeted treatments for esophageal cancer

September 5, 2016
Scientists have discovered that oesophageal cancer can be classified into three different subtypes, paving the way for testing targeted treatments tailored to patients' disease for the first time.

Tumour expression of leptin associated with chemotherapy resistance

February 26, 2014
Patients with the most common type of oesophageal cancer are less likely to respond to chemotherapy when their tumours are high in a protein called leptin, according to research published in the British Journal of Cancer.

Recommended for you

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

A new weapon against bone metastasis? Team develops antibody to fight cancer

December 11, 2017
In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better ...

Insights on how SHARPIN promotes cancer progression

December 11, 2017
Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

Liver cancer: Lipid synthesis promotes tumor formation

December 11, 2017
Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.